Cargando…

Itraconazole Amorphous Solid Dispersion Tablets: Formulation and Compaction Process Optimization Using Quality by Design Principles and Tools

BCS Class II drugs, such as itraconazole (ITZ), exhibit poor solubility (1–4 ng/mL) and so require solubility enhancement. Therefore, ITZ and Kollidon(®) VA64 (KOL) amorphous solid dispersions (ASDs) were produced using hot-melt extrusion (HME) to improve ITZ’s poor solubility. A novel strategy for...

Descripción completa

Detalles Bibliográficos
Autores principales: Triboandas, Hetvi, Pitt, Kendal, Bezerra, Mariana, Ach-Hubert, Delphine, Schlindwein, Walkiria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693276/
https://www.ncbi.nlm.nih.gov/pubmed/36365216
http://dx.doi.org/10.3390/pharmaceutics14112398
_version_ 1784837499079622656
author Triboandas, Hetvi
Pitt, Kendal
Bezerra, Mariana
Ach-Hubert, Delphine
Schlindwein, Walkiria
author_facet Triboandas, Hetvi
Pitt, Kendal
Bezerra, Mariana
Ach-Hubert, Delphine
Schlindwein, Walkiria
author_sort Triboandas, Hetvi
collection PubMed
description BCS Class II drugs, such as itraconazole (ITZ), exhibit poor solubility (1–4 ng/mL) and so require solubility enhancement. Therefore, ITZ and Kollidon(®) VA64 (KOL) amorphous solid dispersions (ASDs) were produced using hot-melt extrusion (HME) to improve ITZ’s poor solubility. A novel strategy for tablet formulations using five inorganic salts was investigated (KCl, NaCl, KBr, KHCO(3) and KH(2)PO(4)). These kosmotopric salts are thought to compete for water hydration near the polymer chain, hence, preventing polymer gelation and, therefore, facilitating disintegration and dissolution. Out of all the formulations, the KCl containing one demonstrated acceptable tensile strength (above 1.7 MPa), whilst providing a quick disintegration time (less than 15 min) and so was selected for further formulation development through a design of the experiment approach. Seven ITZ-KOL-ASD formulations with KCl were compacted using round and oblong punches. Round tablets were found to disintegrate under 20 min, whereas oblong tablets disintegrated within 10 min. The round tablets achieved over 80% ITZ release within 15 min, with six out of seven formulations achieving 100% ITZ release by 30 min. It was found that tablets comprising high levels of Avicel(®) pH 102 (30%) and low levels of KCl (5%) tend to fail the disintegration target due to the strong bonding capacity of Avicel(®) pH 102. The disintegration time and tensile strength responses were modeled to obtain design spaces (DSs) relevant to both round and oblong tablets. Within the DS, several formulations can be chosen, which meet the Quality Target Product Profile (QTPP) requirements for immediate-release round and oblong tablets and allow for flexibility to compact in different tablet shape to accommodate patients’ needs. It was concluded that the use of inorganic salts, such as KCl, is the key to producing tablets of ITZ ASDs with fast disintegration and enhanced dissolution. Overall, ITZ-KOL-ASD tablet formulations, which meet the QTPP, were achieved in this study with the aid of Quality by Design (QbD) principles for formulation and compaction process development and optimization.
format Online
Article
Text
id pubmed-9693276
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96932762022-11-26 Itraconazole Amorphous Solid Dispersion Tablets: Formulation and Compaction Process Optimization Using Quality by Design Principles and Tools Triboandas, Hetvi Pitt, Kendal Bezerra, Mariana Ach-Hubert, Delphine Schlindwein, Walkiria Pharmaceutics Article BCS Class II drugs, such as itraconazole (ITZ), exhibit poor solubility (1–4 ng/mL) and so require solubility enhancement. Therefore, ITZ and Kollidon(®) VA64 (KOL) amorphous solid dispersions (ASDs) were produced using hot-melt extrusion (HME) to improve ITZ’s poor solubility. A novel strategy for tablet formulations using five inorganic salts was investigated (KCl, NaCl, KBr, KHCO(3) and KH(2)PO(4)). These kosmotopric salts are thought to compete for water hydration near the polymer chain, hence, preventing polymer gelation and, therefore, facilitating disintegration and dissolution. Out of all the formulations, the KCl containing one demonstrated acceptable tensile strength (above 1.7 MPa), whilst providing a quick disintegration time (less than 15 min) and so was selected for further formulation development through a design of the experiment approach. Seven ITZ-KOL-ASD formulations with KCl were compacted using round and oblong punches. Round tablets were found to disintegrate under 20 min, whereas oblong tablets disintegrated within 10 min. The round tablets achieved over 80% ITZ release within 15 min, with six out of seven formulations achieving 100% ITZ release by 30 min. It was found that tablets comprising high levels of Avicel(®) pH 102 (30%) and low levels of KCl (5%) tend to fail the disintegration target due to the strong bonding capacity of Avicel(®) pH 102. The disintegration time and tensile strength responses were modeled to obtain design spaces (DSs) relevant to both round and oblong tablets. Within the DS, several formulations can be chosen, which meet the Quality Target Product Profile (QTPP) requirements for immediate-release round and oblong tablets and allow for flexibility to compact in different tablet shape to accommodate patients’ needs. It was concluded that the use of inorganic salts, such as KCl, is the key to producing tablets of ITZ ASDs with fast disintegration and enhanced dissolution. Overall, ITZ-KOL-ASD tablet formulations, which meet the QTPP, were achieved in this study with the aid of Quality by Design (QbD) principles for formulation and compaction process development and optimization. MDPI 2022-11-07 /pmc/articles/PMC9693276/ /pubmed/36365216 http://dx.doi.org/10.3390/pharmaceutics14112398 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Triboandas, Hetvi
Pitt, Kendal
Bezerra, Mariana
Ach-Hubert, Delphine
Schlindwein, Walkiria
Itraconazole Amorphous Solid Dispersion Tablets: Formulation and Compaction Process Optimization Using Quality by Design Principles and Tools
title Itraconazole Amorphous Solid Dispersion Tablets: Formulation and Compaction Process Optimization Using Quality by Design Principles and Tools
title_full Itraconazole Amorphous Solid Dispersion Tablets: Formulation and Compaction Process Optimization Using Quality by Design Principles and Tools
title_fullStr Itraconazole Amorphous Solid Dispersion Tablets: Formulation and Compaction Process Optimization Using Quality by Design Principles and Tools
title_full_unstemmed Itraconazole Amorphous Solid Dispersion Tablets: Formulation and Compaction Process Optimization Using Quality by Design Principles and Tools
title_short Itraconazole Amorphous Solid Dispersion Tablets: Formulation and Compaction Process Optimization Using Quality by Design Principles and Tools
title_sort itraconazole amorphous solid dispersion tablets: formulation and compaction process optimization using quality by design principles and tools
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693276/
https://www.ncbi.nlm.nih.gov/pubmed/36365216
http://dx.doi.org/10.3390/pharmaceutics14112398
work_keys_str_mv AT triboandashetvi itraconazoleamorphoussoliddispersiontabletsformulationandcompactionprocessoptimizationusingqualitybydesignprinciplesandtools
AT pittkendal itraconazoleamorphoussoliddispersiontabletsformulationandcompactionprocessoptimizationusingqualitybydesignprinciplesandtools
AT bezerramariana itraconazoleamorphoussoliddispersiontabletsformulationandcompactionprocessoptimizationusingqualitybydesignprinciplesandtools
AT achhubertdelphine itraconazoleamorphoussoliddispersiontabletsformulationandcompactionprocessoptimizationusingqualitybydesignprinciplesandtools
AT schlindweinwalkiria itraconazoleamorphoussoliddispersiontabletsformulationandcompactionprocessoptimizationusingqualitybydesignprinciplesandtools